Comprehensive control of human papillomavirus infections and related diseases.
Identifieur interne : 003A67 ( PubMed/Corpus ); précédent : 003A66; suivant : 003A68Comprehensive control of human papillomavirus infections and related diseases.
Auteurs : F Xavier Bosch ; Thomas R. Broker ; David Forman ; Anna-Barbara Moscicki ; Maura L. Gillison ; John Doorbar ; Peter L. Stern ; Margaret Stanley ; Marc Arbyn ; Mario Poljak ; Jack Cuzick ; Philip E. Castle ; John T. Schiller ; Lauri E. Markowitz ; William A. Fisher ; Karen Canfell ; Lynette A. Denny ; Eduardo L. Franco ; Marc Steben ; Mark A. Kane ; Mark Schiffman ; Chris J L M. Meijer ; Rengaswamy Sankaranarayanan ; Xavier Castellsagué ; Jane J. Kim ; Maria Brotons ; Laia Alemany ; Ginesa Albero ; Mireia Diaz ; Silvia De SanjoséSource :
- Vaccine [ 1873-2518 ] ; 2013.
Abstract
Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.
DOI: 10.1016/j.vaccine.2013.10.003
PubMed: 24332295
Links to Exploration step
pubmed:24332295Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comprehensive control of human papillomavirus infections and related diseases.</title><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain. Electronic address: admincerp@iconcologia.net.</nlm:affiliation></affiliation></author><author><name sortKey="Broker, Thomas R" sort="Broker, Thomas R" uniqKey="Broker T" first="Thomas R" last="Broker">Thomas R. Broker</name><affiliation><nlm:affiliation>University of Alabama at Birmingham, Biochemistry and Molecular Genetics, Birmingham, Alabama, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Forman, David" sort="Forman, David" uniqKey="Forman D" first="David" last="Forman">David Forman</name><affiliation><nlm:affiliation>Section of Cancer Information, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moscicki, Anna Barbara" sort="Moscicki, Anna Barbara" uniqKey="Moscicki A" first="Anna-Barbara" last="Moscicki">Anna-Barbara Moscicki</name><affiliation><nlm:affiliation>Division of Adolescent Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gillison, Maura L" sort="Gillison, Maura L" uniqKey="Gillison M" first="Maura L" last="Gillison">Maura L. Gillison</name><affiliation><nlm:affiliation>Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Doorbar, John" sort="Doorbar, John" uniqKey="Doorbar J" first="John" last="Doorbar">John Doorbar</name><affiliation><nlm:affiliation>Division of Virology, National Institute for Medical Research, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stern, Peter L" sort="Stern, Peter L" uniqKey="Stern P" first="Peter L" last="Stern">Peter L. Stern</name><affiliation><nlm:affiliation>Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stanley, Margaret" sort="Stanley, Margaret" uniqKey="Stanley M" first="Margaret" last="Stanley">Margaret Stanley</name><affiliation><nlm:affiliation>Department of Pathology, Tennis Court Road, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><nlm:affiliation>Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Castle, Philip E" sort="Castle, Philip E" uniqKey="Castle P" first="Philip E" last="Castle">Philip E. Castle</name><affiliation><nlm:affiliation>Global Cancer Initiative, Chestertown, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schiller, John T" sort="Schiller, John T" uniqKey="Schiller J" first="John T" last="Schiller">John T. Schiller</name><affiliation><nlm:affiliation>Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Markowitz, Lauri E" sort="Markowitz, Lauri E" uniqKey="Markowitz L" first="Lauri E" last="Markowitz">Lauri E. Markowitz</name><affiliation><nlm:affiliation>National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, William A" sort="Fisher, William A" uniqKey="Fisher W" first="William A" last="Fisher">William A. Fisher</name><affiliation><nlm:affiliation>Department of Psychology and Department of Obstetrics and Gynaecology, University of Western Ontario, Social Sciences Centre 7428, London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Canfell, Karen" sort="Canfell, Karen" uniqKey="Canfell K" first="Karen" last="Canfell">Karen Canfell</name><affiliation><nlm:affiliation>Lowy Cancer Research Centre, Prince of Wales Clinical School, The University of NSW, Australia and Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia (past affiliation).</nlm:affiliation></affiliation></author><author><name sortKey="Denny, Lynette A" sort="Denny, Lynette A" uniqKey="Denny L" first="Lynette A" last="Denny">Lynette A. Denny</name><affiliation><nlm:affiliation>Department Obstetrics and Gynaecology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Franco, Eduardo L" sort="Franco, Eduardo L" uniqKey="Franco E" first="Eduardo L" last="Franco">Eduardo L. Franco</name><affiliation><nlm:affiliation>Division of Cancer Epidemiology, McGill University, Montreal, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Steben, Marc" sort="Steben, Marc" uniqKey="Steben M" first="Marc" last="Steben">Marc Steben</name><affiliation><nlm:affiliation>Institut National de Santé Publique du Québec, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Kane, Mark A" sort="Kane, Mark A" uniqKey="Kane M" first="Mark A" last="Kane">Mark A. Kane</name><affiliation><nlm:affiliation>Consultant on Immunization Policy, Mercer Island, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schiffman, Mark" sort="Schiffman, Mark" uniqKey="Schiffman M" first="Mark" last="Schiffman">Mark Schiffman</name><affiliation><nlm:affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Meijer, Chris J L M" sort="Meijer, Chris J L M" uniqKey="Meijer C" first="Chris J L M" last="Meijer">Chris J L M. Meijer</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name><affiliation><nlm:affiliation>Screening Group, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Jane J" sort="Kim, Jane J" uniqKey="Kim J" first="Jane J" last="Kim">Jane J. Kim</name><affiliation><nlm:affiliation>Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brotons, Maria" sort="Brotons, Maria" uniqKey="Brotons M" first="Maria" last="Brotons">Maria Brotons</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Alemany, Laia" sort="Alemany, Laia" uniqKey="Alemany L" first="Laia" last="Alemany">Laia Alemany</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Albero, Ginesa" sort="Albero, Ginesa" uniqKey="Albero G" first="Ginesa" last="Albero">Ginesa Albero</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Diaz, Mireia" sort="Diaz, Mireia" uniqKey="Diaz M" first="Mireia" last="Diaz">Mireia Diaz</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Sanjose, Silvia" sort="De Sanjose, Silvia" uniqKey="De Sanjose S" first="Silvia" last="De Sanjosé">Silvia De Sanjosé</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24332295</idno><idno type="pmid">24332295</idno><idno type="doi">10.1016/j.vaccine.2013.10.003</idno><idno type="wicri:Area/PubMed/Corpus">003A67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comprehensive control of human papillomavirus infections and related diseases.</title><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain. Electronic address: admincerp@iconcologia.net.</nlm:affiliation></affiliation></author><author><name sortKey="Broker, Thomas R" sort="Broker, Thomas R" uniqKey="Broker T" first="Thomas R" last="Broker">Thomas R. Broker</name><affiliation><nlm:affiliation>University of Alabama at Birmingham, Biochemistry and Molecular Genetics, Birmingham, Alabama, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Forman, David" sort="Forman, David" uniqKey="Forman D" first="David" last="Forman">David Forman</name><affiliation><nlm:affiliation>Section of Cancer Information, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moscicki, Anna Barbara" sort="Moscicki, Anna Barbara" uniqKey="Moscicki A" first="Anna-Barbara" last="Moscicki">Anna-Barbara Moscicki</name><affiliation><nlm:affiliation>Division of Adolescent Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gillison, Maura L" sort="Gillison, Maura L" uniqKey="Gillison M" first="Maura L" last="Gillison">Maura L. Gillison</name><affiliation><nlm:affiliation>Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Doorbar, John" sort="Doorbar, John" uniqKey="Doorbar J" first="John" last="Doorbar">John Doorbar</name><affiliation><nlm:affiliation>Division of Virology, National Institute for Medical Research, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stern, Peter L" sort="Stern, Peter L" uniqKey="Stern P" first="Peter L" last="Stern">Peter L. Stern</name><affiliation><nlm:affiliation>Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stanley, Margaret" sort="Stanley, Margaret" uniqKey="Stanley M" first="Margaret" last="Stanley">Margaret Stanley</name><affiliation><nlm:affiliation>Department of Pathology, Tennis Court Road, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><nlm:affiliation>Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Castle, Philip E" sort="Castle, Philip E" uniqKey="Castle P" first="Philip E" last="Castle">Philip E. Castle</name><affiliation><nlm:affiliation>Global Cancer Initiative, Chestertown, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schiller, John T" sort="Schiller, John T" uniqKey="Schiller J" first="John T" last="Schiller">John T. Schiller</name><affiliation><nlm:affiliation>Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Markowitz, Lauri E" sort="Markowitz, Lauri E" uniqKey="Markowitz L" first="Lauri E" last="Markowitz">Lauri E. Markowitz</name><affiliation><nlm:affiliation>National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, William A" sort="Fisher, William A" uniqKey="Fisher W" first="William A" last="Fisher">William A. Fisher</name><affiliation><nlm:affiliation>Department of Psychology and Department of Obstetrics and Gynaecology, University of Western Ontario, Social Sciences Centre 7428, London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Canfell, Karen" sort="Canfell, Karen" uniqKey="Canfell K" first="Karen" last="Canfell">Karen Canfell</name><affiliation><nlm:affiliation>Lowy Cancer Research Centre, Prince of Wales Clinical School, The University of NSW, Australia and Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia (past affiliation).</nlm:affiliation></affiliation></author><author><name sortKey="Denny, Lynette A" sort="Denny, Lynette A" uniqKey="Denny L" first="Lynette A" last="Denny">Lynette A. Denny</name><affiliation><nlm:affiliation>Department Obstetrics and Gynaecology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Franco, Eduardo L" sort="Franco, Eduardo L" uniqKey="Franco E" first="Eduardo L" last="Franco">Eduardo L. Franco</name><affiliation><nlm:affiliation>Division of Cancer Epidemiology, McGill University, Montreal, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Steben, Marc" sort="Steben, Marc" uniqKey="Steben M" first="Marc" last="Steben">Marc Steben</name><affiliation><nlm:affiliation>Institut National de Santé Publique du Québec, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Kane, Mark A" sort="Kane, Mark A" uniqKey="Kane M" first="Mark A" last="Kane">Mark A. Kane</name><affiliation><nlm:affiliation>Consultant on Immunization Policy, Mercer Island, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schiffman, Mark" sort="Schiffman, Mark" uniqKey="Schiffman M" first="Mark" last="Schiffman">Mark Schiffman</name><affiliation><nlm:affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Meijer, Chris J L M" sort="Meijer, Chris J L M" uniqKey="Meijer C" first="Chris J L M" last="Meijer">Chris J L M. Meijer</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name><affiliation><nlm:affiliation>Screening Group, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Jane J" sort="Kim, Jane J" uniqKey="Kim J" first="Jane J" last="Kim">Jane J. Kim</name><affiliation><nlm:affiliation>Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brotons, Maria" sort="Brotons, Maria" uniqKey="Brotons M" first="Maria" last="Brotons">Maria Brotons</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Alemany, Laia" sort="Alemany, Laia" uniqKey="Alemany L" first="Laia" last="Alemany">Laia Alemany</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Albero, Ginesa" sort="Albero, Ginesa" uniqKey="Albero G" first="Ginesa" last="Albero">Ginesa Albero</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Diaz, Mireia" sort="Diaz, Mireia" uniqKey="Diaz M" first="Mireia" last="Diaz">Mireia Diaz</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Sanjose, Silvia" sort="De Sanjose, Silvia" uniqKey="De Sanjose S" first="Silvia" last="De Sanjosé">Silvia De Sanjosé</name><affiliation><nlm:affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24332295</PMID><DateCreated><Year>2013</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>31 Suppl 7</Volume><PubDate><Year>2013</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Comprehensive control of human papillomavirus infections and related diseases.</ArticleTitle><Pagination><MedlinePgn>H1-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.10.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)01346-7</ELocationID><Abstract><AbstractText>Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>F Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain. Electronic address: admincerp@iconcologia.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broker</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Biochemistry and Molecular Genetics, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Section of Cancer Information, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moscicki</LastName><ForeName>Anna-Barbara</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Division of Adolescent Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillison</LastName><ForeName>Maura L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doorbar</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Medical Research, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanley</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tennis Court Road, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbyn</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poljak</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuzick</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castle</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Global Cancer Initiative, Chestertown, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Lauri E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Psychology and Department of Obstetrics and Gynaecology, University of Western Ontario, Social Sciences Centre 7428, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canfell</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Lowy Cancer Research Centre, Prince of Wales Clinical School, The University of NSW, Australia and Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia (past affiliation).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denny</LastName><ForeName>Lynette A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Eduardo L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steben</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Consultant on Immunization Policy, Mercer Island, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffman</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijer</LastName><ForeName>Chris J L M</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>Rengaswamy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Screening Group, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellsagué</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jane J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brotons</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alemany</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albero</LastName><ForeName>Ginesa</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sanjosé</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA83679</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA160744-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U117584278</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RC1AI86051</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54CA164336</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC U117584278</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CA36200</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_13050</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R37 CA51323</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>A10404</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R37 CA051323</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ReprintOf"><RefSource>Vaccine. 2013 Nov 22;31 Suppl 8:I1-31</RefSource><PMID Version="1">24229716</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anal cancer</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">HPV testing</Keyword><Keyword MajorTopicYN="N">HPV vaccination</Keyword><Keyword MajorTopicYN="N">Oropharyngeal cancer</Keyword><Keyword MajorTopicYN="N">Penile cancer</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Screening</Keyword><Keyword MajorTopicYN="N">Vaginal cancer</Keyword><Keyword MajorTopicYN="N">Vulvar cancer</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Albero</LastName><ForeName>Ginesa</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alemany</LastName><ForeName>Laia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anttila</LastName><ForeName>Ahti</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arbyn</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banks</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergeron</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belinson</LastName><ForeName>Jerome L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkhof</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosch</LastName><ForeName>F Xavier</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bravo</LastName><ForeName>Ignacio G</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bray</LastName><ForeName>Freddie</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broker</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brotherton</LastName><ForeName>Julia M L</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruni</LastName><ForeName>Laia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burchell</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canfell</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castellsagué</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castle</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chesson</LastName><ForeName>Harrell</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chevarie-Davis</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cubie</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuzick</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deeks</LastName><ForeName>Shelley L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Martel</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denny</LastName><ForeName>Lynette A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Sanjosé</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz</LastName><ForeName>Mireia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillner</LastName><ForeName>Joakim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doorbar</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Einstein</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferlay</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiander</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>William A</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franceschi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>Eduardo L</ForeName><Initials>EL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garland</LastName><ForeName>Suzanne M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillison</LastName><ForeName>Maura L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giuliano</LastName><ForeName>Anna R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>Marc T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gravitt</LastName><ForeName>Patti</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hampson</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heard</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iftner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isidean</LastName><ForeName>Sandra D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jensen</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeronimo</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kane</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jane J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinney</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitchener</LastName><ForeName>Henry C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kjaer</LastName><ForeName>Susanne K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kocjan</LastName><ForeName>Boštjan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koliopoulos</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulasingam</LastName><ForeName>Shalini L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacey</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaMontagne</LastName><ForeName>D Scott</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazcano-Ponce</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorincz</LastName><ForeName>Attila T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lortet-Tieulent</LastName><ForeName>Joannie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Lauri E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meijer</LastName><ForeName>Chris J L M</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moscicki</LastName><ForeName>Anna-Barbara</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naucler</LastName><ForeName>Pontus</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogilvie</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palefsky</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peto</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinto</LastName><ForeName>Ligia A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plummer</LastName><ForeName>Martyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poljak</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qiao</LastName><ForeName>You-Lin</ForeName><Initials>YL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quint</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronco</LastName><ForeName>Guglielmo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>Rengaswamy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiffman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiller</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serrano</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snijders</LastName><ForeName>Peter J F</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soerjomataram</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanley</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steben</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Bettie M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoler</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szarewski</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trimble</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsu</LastName><ForeName>Vivien</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Damme</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Burg</LastName><ForeName>Sjoerd H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicari</LastName><ForeName>Andrea S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vignat</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Knebel Doeberitz</LastName><ForeName>Magnus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorsters</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wittet</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24332295</ArticleId><ArticleId IdType="pii">S0264-410X(13)01346-7</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2013.10.003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24332295
|texte= Comprehensive control of human papillomavirus infections and related diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24332295" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |